REYKJAVIK, Islande–(BUSINESS WIRE)–Oculis a annoncé aujourd’hui avoir bouclé un tour de financement de série A mené par Brunnur Ventures et Silfurberg. Le capital nouvellement levé soutiendra le développement continu de la plateforme brevetée de libération de médicaments de la société pour les nanoparticules solubilisantes (SNP) et des candidats médicaments de la société, incluant les premières gouttes ophtalmiques topiques pour le traitement de l’œdème maculaire diabétique. Plateforme de lib
REYKJAVIK, Islanda–(BUSINESS WIRE)–Oculis ha annunciato oggi la chiusura del round di finanziamenti di Serie A, condotta da Brunnur Ventures e Silfurberg. Il nuovo capitale servirà a finanziare lo sviluppo continuo della piattaforma di rilascio dei farmaci a base di nanoparticelle solubilizzanti (solubilizing nanoparticle, SNP) brevetto esclusivo della società, e dei candidati farmaci prodotti dall’azienda, compreso il primo trattamento topico a base di collirio per l’edema maculare diabetico
REYKJAVIK, Island–(BUSINESS WIRE)–Oculis meldete heute den Abschluss einer Serie-A-Finanzierungsrunde unter der Leitung von Brunnur Ventures und Silfurberg. Das frische Kapital dient der Förderung der fortgesetzten Entwicklung der patentierten Drug Delivery Platform von Oculis für solubilisierende Nanopartikel (SNP) und der Arzneimittelkandidaten des Unternehmens, einschließlich der ersten topischen Augentropfen zur Behandlung des diabetischen Makulaödems (DME). SNP Drug Delivery Platform – D
A web-based tool and health care professional training improved communication during patient handoffs and reduced medical errors, according to data published in JAMA Internal Medicine.”Communication among health care personnel is vulnerable to error du…
SAN FRANCISCO — At the American Society of Retina Specialists meeting here, Andrew Antoszyk, MD, discusses results of the DRCR.net Protocol S study, a randomized clinical trial comparing intravitreal ranibizumab with panretinal photocoagulation in the treatment of proliferative diabetic retinopathy.
Researchers have documented 35 eyes with severe hemorrhagic occlusive retinal vasculitis after treatment with vancomycin during cataract procedures. Medscape Medical News